

1 **Spinal cord stimulation exerts neuroprotective effects against experimental**
2 **Parkinson's disease**

3

4 Aiko Shinko, M.D.¹, Takashi Agari, M.D.¹, Ph.D., Masahiro Kameda, M.D., Ph.D.¹,
5 Takao Yasuhara, M.D., Ph.D.¹, Akihiko Kondo, M.D., Ph.D.¹, Judith Thomas Tayra,
6 M.D., Ph.D.¹, Kenichiro Sato, M.D.¹, Tatsuya Sasaki, M.D.¹, Susumu Sasada, M.D.¹,
7 Hayato Takeuchi, M.D.¹, Takaaki Wakamori, M.A.¹, Cesario V. Borlongan, Ph.D.²,
8 Isao Date, M.D., Ph.D.¹

9

10 1) Department of Neurological Surgery, Okayama University Graduate School of
11 Medicine, Okayama, JAPAN

12 2) Department of Neurosurgery, University of South Florida College of Medicine,
13 Tampa, Florida, USA

14

15 **Send Correspondence to**

16 Takashi Agari, M.D., Ph.D.

17 Department of Neurological Surgery, Okayama University Graduate School of
18 Medicine

19 Address: 2-5-1, Shikata-cho, Kita-ku, Okayama, 700-8558, JAPAN

20 Phone: 81-86-235-7336 Fax: 81-86-227-0191

21 E-mail: agarit@cc.okayama-u.ac.jp

22

23 **Key words:** neuroprotective effects, Parkinson's disease, spinal cord stimulation,

24 vascular endothelial growth factor

1 ***Abstract***

2 In clinical practice, deep brain stimulation (DBS) is effective for treatment of motor
3 symptoms in Parkinson's disease (PD). However, the mechanisms have not been
4 understood completely. There are some reports that electrical stimulation exerts
5 neuroprotective effects on the central nervous system diseases including cerebral
6 ischemia, head trauma, epilepsy and PD, although there are a few reports on
7 neuroprotective effects of spinal cord stimulation (SCS). We investigated the
8 neuroprotective effects of high cervical SCS on PD model of rats. Adult female
9 Sprague-Dawley rats received hour-long SCS (2, 50 or 200Hz) with an epidural
10 electrode at C1-2 level for 16 consecutive days. At 2 days after initial SCS,
11 6-hydroxydopamine (6-OHDA) was injected into the right striatum of rats. Behavioral
12 evaluations of PD symptoms were employed, including cylinder test and
13 amphetamine-induced rotation test performed at 1 and 2 weeks after 6-OHDA injection.
14 Animals were subsequently euthanized for immunohistochemical investigations. In
15 order to explore neurotrophic and growth factor upregulation induced by SCS, another
16 cohort of rats that received 50Hz SCS was euthanized at 1 and 2 weeks after lesion for
17 protein assays. Behavioral tests revealed that the number of amphetamine-induced
18 rotations decreased in SCS groups. Immunohistochemically, tyrosine hydroxylase
19 (TH)-positive fibers in the striatum were significantly preserved in SCS groups.
20 TH-positive neurons in the substantia nigra pars compacta were significantly preserved
21 in 50Hz SCS group. The level of vascular endothelial growth factor (VEGF) was
22 upregulated by SCS at 1 week after the lesion. These results suggest that high cervical
23 SCS exerts neuroprotection in PD model of rats, at least partially by upregulation of
24 VEGF. SCS is supposed to suppress or delay PD progression and might become a less

- 1 invasive option for PD patients, although further preclinical and clinical investigations
- 2 are needed to confirm the effectiveness and safety.

1 **Introduction**

2 Parkinson's disease (PD) is a progressive neurodegenerative disease caused by
3 the loss of dopaminergic neurons in the nigrostriatal system. Levodopa treatment
4 remains the gold standard of treatment for PD, but only supportive effects are achieved
5 with adverse effects (e.g., dyskinesias) over time [1] necessitating the need for
6 innovative therapies.

7 In surgical treatment, deep brain stimulation is effective for motor symptoms of
8 PD, but the inclusion criteria have been limited. In 2009, Fuentes and colleagues
9 reported that spinal cord stimulation (SCS) restores locomotion in animal models of PD
10 [2]. In the clinic, SCS is an alternative approach for treatment of neuropathic pain after
11 medication has failed. Previously, laboratory studies have shown that SCS increases
12 cerebral blood flow in animal models of cerebral ischemia or spasms after subarachnoid
13 hemorrhage through vasodilation effects with subsequent behavioral amelioration
14 [3-10], and recently, a study demonstrated that SCS at the high thoracic level for PD
15 model of rats has neuroprotective effects [11].

16 Neuroprotective effects of electrical stimulation have been demonstrated in our
17 preclinical reports [12, 13], but the mechanisms of action remain incompletely
18 understood. In ischemic stroke rats, neurotrophic factors (glial cell line-derived
19 neurotrophic factor: GDNF; brain-derived neurotrophic factor: BDNF), and vascular
20 endothelial growth factor (VEGF) were upregulated by cortical stimulation [12].
21 Moreover, in PD rats, stimulation of the subthalamic nucleus generated neuroprotective
22 effects [14-17], with BDNF implicated as a therapeutic target for the observed
23 neuroprotection [16]. In the present study, we characterized behaviorally and
24 immunohistochemically neuroprotective effects of high cervical SCS on PD rats, with

- 1 emphasis on the likely involvement of secretion of neurotrophic and growth factors as a
- 2 key mechanism of action.

1 **Materials and Methods**

2 *Ethics statement*

3 All animal procedures in this study were specifically approved by the
4 Institutional Animal Care and Use Committee of Okayama University Graduate School
5 of Medicine (protocol #OKU-2012311).

6

7 *Animals*

8 Adult female Sprague-Dawley rats (Charles River, Japan; n=80) weighing
9 200-250g at the beginning of the experiment were used. They were singly housed per
10 cage in a temperature and humidity-controlled room, maintained on a 12-hour light/dark
11 cycle, with free access to food and water.

12

13 *Experimental design*

14 In order to evaluate the neuroprotective effects of high cervical SCS, rats were
15 classified into 4 groups, namely, control group and 2, 50 and 200Hz SCS groups
16 respectively (total 40 rats, each group n=10). All rats received the lower half of C1 and
17 C2 laminectomy under general anesthesia with implantation of a monopolar electrode.
18 We selected the high cervical cord as a target, because we expected that the high
19 cervical SCS might activate upper level cord and brain stem. Subsequently rats in SCS
20 groups received hour-long electrical stimulations daily for 16 days, but rats in control
21 group received no electrical stimulation. At 2 days after initial SCS,
22 6-hydroxydopamine (6-OHDA) was injected into the right striatum of all rats as
23 described previously (see below). We started SCS at 2 days before 6-OHDA
24 administration, because we expected the pre-conditioning effect of SCS, and stimulation

1 continued for 2 weeks (1hour/ day) after 6-OHDA administration in which
2 degeneration of dopaminergic neurons is going on. For behavioral evaluations of PD
3 symptoms, cylinder test was performed at 1 and 2 weeks after 6-OHDA injection and
4 amphetamine-induced rotation test was performed at 2 weeks after the lesion. In detail,
5 we conducted cylinder test just before stimulation at 1 week after 6-OHDA
6 administration. At 2 weeks after 6-OHDA administration, cylinder test and
7 amphetamine-induced rotation test in twelve hours after the last SCS to minimize the
8 effects of anesthetic.

9 Following behavioral tests, animals were euthanized for immunohistochemical
10 investigations. In order to evaluate the relationship between SCS and secretion of
11 neurotrophic and growth factors, another cohort of rats was randomly assigned to one of
12 two groups (total 40 rats: control group and 50Hz SCS group, n=20, respectively) using
13 the corresponding procedures as described above. These experimental designs are
14 shown in Fig. 1A and B.

15

16 *Implantation of an electrode*

17 All rats were deeply anesthetized with pentobarbital (35 mg/kg, i.p.) and placed
18 in a stereotaxic instrument (Narishige, Japan). Laminectomy of the lower half of C1 and
19 C2 was performed. A silver ball electrode with diameter of 2 mm was implanted in the
20 epidural space over the dorsal column. A ground electrode was placed in the skull of
21 rats with the connection side of the electrode outside the body through the subcutaneous
22 lead. The systems used in this study are shown in Fig. 1C and D.

23

24 *Electrical stimulation*

1 Rats in both control group and SCS groups were anesthetized with pentobarbital
2 (10 mg/kg, i.p.) with subsequent connection of the electrode to the stimulation device
3 (SEN-7203, NIHON KOHDE, Japan). Thereafter, rats in SCS groups received
4 hour-long stimulations daily for 16 days. To minimize the effects of anesthesia, we used
5 a very small amount of anesthetic, so rats were immobilized only during stimulation.
6 We also used the 26G thin needle for injection.

7 The parameter of stimulating pulses was adjusted to a variety of frequency (2,
8 50, or 200Hz) based on the results of our previous studies and another basic reports
9 demonstrating therapeutic efficacy [2, 4, 7, 12], and intensities were individually
10 adjusted according to the 80% motor threshold intensity. After the stimulation, the
11 electrode connection was removed, and rats were allowed to move freely.

12

13 *6-OHDA lesion*

14 All rats were anesthetized with sodium pentobarbital (35 mg/kg, i.p.) and
15 placed in a stereotaxic instrument (Narishige, Japan). Twenty μg of 6-OHDA (4 μl of 5
16 mg/ml dissolved in saline containing 0.2 mg/ml ascorbic acid; Sigma, USA) was
17 injected into the right striatum with a 28G Hamilton syringe. The lesion coordinates
18 were as follows: 1 mm anterior to the bregma, 3 mm lateral to the sagittal suture, and 5
19 mm ventral to the surface of the brain with the tooth-bar set at -3.0 mm [18]. The
20 injection rate was 1 $\mu\text{l}/\text{min}$. After the injection, the syringe was left in place for
21 additional 5 minutes before being it was retracted slowly (1 mm/min).

22

23 *Behavioral tests*

24 *Cylinder test:* We performed the cylinder test, which assessed the degree of

1 forepaw asymmetry, at 1 and 2 weeks after 6-OHDA injection. Rats were placed in a
2 transparent cylinder (diameter: 20 cm, height: 30 cm) for 3 minutes and the number of
3 forepaw contacts to the cylinder wall was counted [19]. The score of cylinder test in this
4 study was calculated as a contralateral bias, that is, [(the number of contacts with the
5 contralateral limb)-(the number of contacts with the ipsilateral limb)/ (the number of
6 total contacts) x100] [20].

7 *Amphetamine-induced rotation test:* All rats were tested with amphetamine (3.0
8 mg/kg, Dainippon Sumitomo Pharma, Japan) at 2 weeks after 6-OHDA injection. The
9 rotational behaviors were assessed for 90 minutes with a video camera. Full 360° turns
10 ipsilateral to the lesion were counted.

11

12 *Immunohistochemical investigations*

13 All rats were euthanized with an overdose of pentobarbital (100 mg/kg) at 2
14 weeks after 6-OHDA injection, and perfused transcardially with 200 ml of cold PBS
15 and 200 ml of 4% paraformaldehyde (PFA) in PBS. Brains were removed and
16 post-fixed in the same fixative overnight at 4 degrees C, and subsequently stored in 30%
17 sucrose in PBS until completely submerged. The brains were coronally sectioned at the
18 thickness of 40 µm. Free-floating sections for TH staining were blocked by 3%
19 hydrogen peroxide in 70% methanol for 7 minutes. Sections were washed 3 times for 5
20 minutes in PBS. Sections were then incubated overnight at 4 degrees C with rabbit
21 anti-TH antibody (1:500; Chemicon, Temecula, CA, USA) with 10% normal horse
22 serum. After several rinses in PBS, sections were incubated for 1 hour in biotinylated
23 donkey anti-rabbit IgG (1:500; Jackson Immuno-Research Lab, West Grove, PA, USA),
24 then for 30 minutes in avidin-biotin-peroxidase complex (Vector Laboratories,

1 Burlingame, CA, USA). Subsequently, the sections were treated with 3,
2 4-diaminobenzidine (DAB; Vector) and hydrogen peroxide, mounted on albumin-coated
3 slides and embedded with cover glass.

4

5 *Morphological analyses*

6 The density of TH-positive fibers in the striatum of rats was determined and
7 analyzed with a computerized analysis system as described previously [21]. Five
8 sections at 0.5 ± 1.0 mm anterior to the bregma were randomly selected for quantitative
9 analyses [18]. The two areas adjacent to the needle tract of lesioned side and the
10 symmetrical areas in the contralateral side were analyzed, respectively. The percentages
11 of lesion to the intact side were evaluated in each section and the averages were used for
12 statistical analyses. The images were computer-processed into binary images using an
13 appropriate threshold (Scion Image, Scion Corp., Frederick, MD, USA). The areas were
14 then calculated and used for statistical analyses. According to our previous publication
15 for counting the number of TH-positive neurons [22], every fifth 40 μm -thick coronal
16 section through the substantia nigra pars compacta (SNc) was explored using 3 coronal
17 sections, respectively, at 4.8, 5.3, and 5.8 mm posterior to the bregma. The number of
18 cells was summed up in each group. The percentage to the intact side was analyzed and
19 the average was used for the statistical analyses.

20

21 *ELISA Analyses*

22 For protein assay, fresh brains from rats of control and 50Hz SCS groups were
23 quickly harvested after decapitation of animals anesthetized with an overdose of
24 pentobarbital (100 mg/kg, i.p.) at 1 and 2 weeks after 6-OHDA lesion. Brains were

1 sliced at the thickness of 2 mm. The brain tissue of the striatum was punched out using a
2 biopsy punch (3 mm-hole, Kai corporation and Kai industries co., ltd, Japan) as shown
3 in Fig. 1E. Brain tissues were then homogenized in T-PER (Pierce, Rockfold, IL) and
4 centrifuged at 10,000G for 10 minutes at 4 degrees C, and the supernatant was obtained.
5 Brain VEGF and GDNF levels were measured by the usage of rat VEGF ELISA assay
6 kit (IBL, Japan) and rat GDNF ELISA assay kit (Abnova, Taiwan).

7

8 *Statistical Analyses*

9 Cylinder test data were evaluated statistically using repeated measures of
10 ANOVA (analysis of variance), while the data from amphetamine-induced rotation test,
11 immunohistochemistry, and ELISA were evaluated statistically using single ANOVA,
12 with subsequent post hoc Scheffe's test. Statistical significance was preset at $p < 0.05$.
13 Mean values are presented with standard deviation (SD).

14

15 **Results**

16 *Behavioral tests*

17 *Cylinder test:* In 2Hz and 50Hz SCS groups, the treated animals appeared to
18 perform better in the cylinder test than those in 200Hz SCS and control groups, but did
19 not reach statistical significance at 1 and 2 weeks after 6-OHDA injection (Contralateral
20 bias: 2Hz: 69 ± 38.0 and $49 \pm 54.1\%$; 50Hz: 59 ± 46.0 and $29 \pm 35.6\%$; 200Hz: 71 ± 23.1 and
21 $83 \pm 22.5\%$; control group: 60 ± 25.4 and $66 \pm 20.7\%$, at 1 and 2 weeks respectively;
22 repeated-measures ANOVA; $F_{(3, 29)} = 1.871$, $p = 0.1566$) (Fig. 2A).

23 *Amphetamine-induced rotation test:* The number of amphetamine-induced
24 rotations at 2 weeks after 6-OHDA injection in animals exposed to 2Hz, 50Hz, and

1 200Hz SCS (2Hz: 667 ± 344 turns/90min; 50Hz: 575 ± 230 turns/90min; 200Hz: 759 ± 307
2 turns/90min respectively, Fig. 2B) decreased compared to control group (1037 ± 192
3 turns/90min, Fig. 2B). In addition, the number of amphetamine-induced rotations
4 significantly decreased in the other cohort of animals exposed to 50Hz SCS compared
5 to that in control group (ANOVA; $F_{(3, 32)}=5.212$; $p=0.0048$; $p \text{ value}<0.05$).

6

7 *Immunohistochemical investigations*

8 Rats in all SCS groups showed significant preservation of TH-positive fibers in
9 the striatum (2Hz: $78\pm9.9\%$; 50Hz: $96\pm5.2\%$; 200Hz: $83\pm7.5\%$ relative to the intact
10 side, respectively, Fig. 3), compared to those in control group ($64\pm11.1\%$, ANOVA; $F_{(3, 33)}=20.731$;
11 $p<0.0001$; $p \text{ value}<0.05$, Fig. 3).

12 The rats that received 50Hz SCS also displayed significant preservation of
13 TH-positive neurons in the SNc ($66\pm9.2\%$ for 50Hz SCS group relative to the intact
14 side, ANOVA; $F_{(3, 31)}=5.155$; $p=0.0052$; $p \text{ value}<0.05$, Fig. 4), compared to those in
15 control group ($44\pm14.4\%$ relative to the intact side, Fig. 4).

16

17 *Protein assay for neurotrophic and growth factors*

18 VEGF level of the lesioned striatum in rats that received 50Hz SCS increased
19 compared to that of control group at 1 and 2 weeks after 6-OHDA lesion, respectively
20 (50Hz: 35.8 ± 7.4 pg/ml and 54.3 ± 26.8 pg/ml; control group: 25.5 ± 6.9 pg/ml and
21 44.6 ± 11.6 pg/ml at 1 and 2 weeks, respectively, Fig. 5A and B) and reached statistical
22 significance at 1 week after 6-OHDA lesion (ANOVA; $F_{(3, 42)}=0.0006$; p
23 $\text{value}<0.05$, Fig. 5A). On the other hand, 50Hz SCS did not increase GDNF level in the
24 striatum at 1 and 2 weeks after 6-OHDA lesion compared to that of rats in control group

1 (50Hz: 113.3 ± 17.1 pg/ml and 592.4 ± 256.3 pg/ml; control group: 99.0 ± 32.8 pg/ml and
2 542.5 ± 161.3 pg/ml, at 1 and 2 weeks, respectively, Fig. 5C and D).

3

4 **Discussion**

5 The present study showed that SCS exerted neuroprotective effects on PD
6 model of rats characterized by behavioral and immunohistochemical amelioration. The
7 neuroprotective effects of 50Hz SCS appeared optimal, compared to those of 2Hz and
8 200Hz SCS. VEGF level increased in the lesioned striatum of rats that received 50Hz
9 SCS, implicating that the neuroprotective effects of 50Hz SCS may partially involve a
10 VEGF-mediated mechanism.

11

12 *SCS parameter*

13 There are few reports about the effect of SCS for animal model of PD, and
14 therefore there is almost no report that would be helpful for our choice of electrical
15 parameter. For this reason, we had chosen the parameters referring to the report of
16 electrical stimulation experiments for the various central nervous diseases. In the
17 previous report about the effect for the cerebral blood flow, 50Hz SCS had the highest
18 increasing effect of the cerebral blood flow [23]. In reference to this report, the other
19 majority of SCS experiments about the cerebral blood flow are used 50Hz SCS. On the
20 other hand, according to our electrical stimulation experiments on cerebral infarction
21 model of rats, we had reported that low frequency stimulation (i.e. 2 or 10Hz) were
22 effective for reduction of volume of cerebral infarction [12]. Furthermore, 333Hz SCS
23 are used in the report of the effect of SCS for PD model [2]. Referring to these reports,
24 we had selected these three stimulation frequencies (i.e. 2, 50, and 200Hz). It has been

1 reported that 200 or 2000Hz SCS had no increasing effect in cerebral blood flow [24].
2 We have considered that this result is a one of the reason why 200 Hz SCS hasn't
3 obtained good effect in this study. We also have impression that the 200Hz SCS might
4 damage to rat spinal cord, and rat itself.

5

6 *Current status of SCS*

7 In clinical practice, SCS was introduced in 1967 for the treatment of chronic
8 intractable neuropathic pain [25]. Today, SCS targeting the dorsal column is clinically
9 used as a valuable treatment for neuropathic pain, especially for failed back surgery
10 syndrome (FBSS) [26], complex regional pain syndrome type 1 [27]. The mechanisms
11 of pain relief have not yet been well elucidated. Previously, the gate control theory
12 advanced the notion that pain signals from the peripheral nerve were presynaptically
13 inhibited in the spinal cord [28]. However in recent years, other neurochemical factors
14 and electrophysiological factors have been thought to mediate pain [29-36]. On the
15 other hand, the increase of cerebral blood flow has been shown to accompany the
16 therapeutic effects of SCS [37-39]. In animal experiments, several studies have
17 demonstrated efficacy of SCS in models of cerebral infarction or vasospasm after
18 subarachnoid hemorrhage [3-10]. SCS was also used for the treatment against cardiac
19 ischemia [40], or postoperative ileus [41]. The mechanism of vasodilation by SCS
20 appears to be related to suppression of sympathetic activity [42, 43], as well as indirect
21 activation of the brainstem or cerebellar vasomotor centers [6, 7, 44], and/or causing the
22 release of rapid vasoactive substances such as nitric oxide or calcitonin gene-related
23 peptide [45-47]. Moreover, SCS was accompanied by dilation of small arteries in the
24 subarachnoid space without visible changes of intraparenchymal vessels in diameter [4],

1 altogether supporting the concept of a humoral effect by SCS. Accordingly, assessment
2 of alterations in the vascular system (i.e., monitoring VEGF levels as in the present
3 study) may provide insights into the neuroprotective effects of SCS.

4

5 *Neurotrophic and growth factors and electrical stimulation*

6 Electrical stimulation has been used in the clinical setting for various diseases
7 of the central nervous system, including epilepsy, central pain, and psychological
8 disorders like schizophrenia and depression. Electrical stimulation of the cerebral cortex
9 increased the expression of neurotrophic and growth factors, such as GDNF, BDNF and
10 VEGF [12]. Previously we demonstrated that parenchymal stimulation exhibited
11 significant upregulation of GDNF and VEGF for chronic-phase ischemic stroke model
12 of animals [13]. And in PD rats, stimulation of subthalamic nucleus increases BDNF in
13 nigrostriatal system [16]. However, there is almost no report on the relationship between
14 SCS and neurotrophic and growth factors. Very recently, Yadav and colleagues
15 demonstrated the possibility that high thoracic SCS might have neuroprotective effects
16 for PD model of rat, and pronounced that SCS might increase production or delivery of
17 neurotrophic factors [11]. In our study, we demonstrated that VEGF increased in the
18 lesioned striatum of rats that received SCS. SCS didn't upregulate BDNF (data not
19 shown). As previously reported, SCS may increase cerebral blood flow and enhance
20 patency of the cerebral microvasculature [3-10], again invoking the effects of SCS on
21 the vascular system. VEGF is known to enhance glial proliferation and angiogenesis
22 with synergistic neuroprotective effects [48-51]. Neuroprotective effects have also been
23 associated with neurogenesis and intrinsic neurorestoration [50, 52-53]. Furthermore,
24 increased VEGF signaling may result in neuroprotective effects thereby enhancing the

1 survival of dopaminergic neurons, which suggests a potential therapeutic application for
2 PD [49-50, 54]. Additionally, VEGF may protect dopaminergic neurons by
3 improvement of microcirculation through enhanced angiogenesis. These multi-pronged
4 vasculature-based neuroprotective pathways might have been elicited by the observed
5 VEGF elevation following SCS treatment in our PD animals.

6

7 *SCS and Parkinson's disease*

8 In 2009, Fuentes and co-workers reported that SCS restores locomotion in
9 animal models of PD [2], indicating that SCS may alleviate PD-related akinesia. It is
10 known that neural fibers which are most activated by SCS might be the superficial
11 fibers of the dorsal columns, although the underlying mechanisms are still not well
12 understood. SCS may facilitate corticostriatal oscillatory mode of neuronal activity with
13 subsequent increase of locomotion [2]. However, a clinical study showed that SCS
14 failed to relieve akinesia or restore locomotion in PD [55]. This discrepancy may be due
15 to the limitation of the PD model in approximating the clinical pathophysiology, as well
16 as the differences in SCS stimulation parameters in the laboratory and the clinic. In the
17 present study we showed that 50Hz SCS may afford neuroprotective effects on the
18 nigrostriatal system of PD rats. Yet, it has translational limitations as patients receive
19 SCS after PD. Yadav and colleagues demonstrated that SCS had neurorestorative effect.
20 In their protocol, SCS started one week after 6-OHDA administration [11]. We must
21 conduct the additional studies, which demonstrate the neurorestorative effects of SCS
22 on PD model of rats in the future.

23

24 **Conclusions**

1 This study demonstrates that high cervical SCS exerts neuroprotective effects
2 in PD model of rats by increasing VEGF levels in the lesioned striatum. SCS is
3 supposed to suppress or delay PD progression. In the future, SCS may become a less
4 invasive therapeutic option for PD patients, although further preclinical experiments are
5 warranted to confirm the efficacy, safety, and mechanisms of action.

1 Reference

- 2 1. Rajput AH, Fenton ME, Di Paolo T, Sitte H, Pifl C, et al. (2004) Human brain
3 dopamine metabolism in levodopa-induced dyskinesia and wearing-off. *Parkinsonism*
4 *Relat Disord* 10:221-226.
- 5 2. Fuentes R, Petersson P, Siesser WB, Caron MG, Nicoletis MA (2009) Spinal
6 cord stimulation restores locomotion in animal models of Parkinson's disease. *Science*
7 323:1578-1582.
- 8 3. Gurelik M, Kayabas M, Karadag O, Goksel HM, Akyuz A, et al. (2005)
9 Cervical spinal cord stimulation improves neurological dysfunction induced by cerebral
10 vasospasm. *Neuroscience* 134:827-832.
- 11 4. Lee JY, Huang DL, Keep R, Sagher O (2008) Effect of electrical stimulation of
12 the cervical spinal cord on blood flow following subarachnoid hemorrhage. *J Neurosurg*
13 109:1148-1154.
- 14 5. Patel S, Huang D-L, Sagher O (2004) Evidence for a central pathway in the
15 cerebrovascular effects of spinal cord stimulation. *Neurosurgery* 55:201-206.
- 16 6. Patel S, Huang DL, Sagher O (2003) Sympathetic mechanisms in cerebral
17 blood flow alterations induced by spinal cord stimulation. *J Neurosurg* 99:754-761.
- 18 7. Sagher O, Huang DL, Keep RF (2003) Spinal cord stimulation reducing infarct
19 volume in a model of focal cerebral ischemia in rats. *J Neurosurg* 99:131-137.
- 20 8. Visocchi M, Argiolas L, Meglio M, Cioni B, Basso PD, et al. (2001) Spinal
21 cord stimulation and early experimental cerebral spasm: the "functional monitoring" and
22 the "preventing effect". *Acta Neurochir (Wien)* 143:177-185.
- 23 9. Visocchi M, Di Rocco F, Meglio M (2001) Protective effect of spinal cord
24 stimulation on experimental early cerebral vasospasm. Conclusive results. *Stereotact*

- 1 Funct Neurosurg 76:269-275.
- 2 10. Yang X, Farber JP, Wu M, Foreman RD, Qin C (2008) Roles of dorsal column
3 pathway and transient receptor potential vanilloid type 1 in augmentation of cerebral
4 blood flow by upper cervical spinal cord stimulation in rats. *Neuroscience* 152:950-958.
- 5 11. Yadav AP, Fuentes R, Zhang H, Vinholo T, Wang CH, et al. (2014) Chronic
6 spinal cord electrical stimulation protects against 6-hydroxydopamine lesions. *Sci Rep*.
7 DOI: 10.1038/srep03839.
- 8 12. Baba T, Kameda M, Yasuhara T, Morimoto T, Kondo A, et al. (2009) Electrical
9 stimulation of the cerebral cortex exerts antiapoptotic, angiogenic, and
10 anti-inflammatory effects in ischemic stroke rats through phosphoinositide 3-kinase/Akt
11 signaling pathway. *Stroke* 40:e598-605.
- 12 13. Morimoto T, Yasuhara T, Kameda M, Baba T, Kuramoto S, et al. (2011) Striatal
13 stimulation nurtures endogenous neurogenesis and angiogenesis in chronic-phase
14 ischemic stroke rats. *Cell Transplant* 20:1049-1064.
- 15 14. Harnack D, Meissner W, Jira JA, Winter C, Morgenstern R, et al. (2008)
16 Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus
17 preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism. *Exp*
18 *Neurol* 210:257-260.
- 19 15. Maesawa S, Kaneoke Y, Kajita Y, Usui N, Misawa N, et al. (2004) Long-term
20 stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of
21 dopaminergic neurons. *J Neurosurg* 100:679-687.
- 22 16. Spieles-Engemann AL, Steece-Collier K, Behbehani MM, Collier TJ,
23 Wohlgenant SL, et al. (2011) Subthalamic nucleus stimulation increases brain derived
24 neurotrophic factor in the nigrostriatal system and primary motor cortex. *J Parkinson*

- 1 Dis 1:123-136.
- 2 17. Temel Y, Visser-Vandewalle V, Kaplan S, Kozan R, Daemen MA, et al. (2006)
3 Protection of nigral cell death by bilateral subthalamic nucleus stimulation. *Brain Res*
4 1120:100-105.
- 5 18. Paxions G, Watason G (1998) *The Rat Brain in Stereotaxic Coordinates*. San
6 Diego: Academic Press.
- 7 19. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST (2000) CNS
8 plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of
9 stroke, cortical ablation, parkinsonism and spinal cord injury. *Neuropharmacology*
10 39:777-787.
- 11 20. Roof RL, Schielke GP, Ren X, Hall ED (2001) A comparison of long-term
12 functional outcome after 2 middle cerebral artery occlusion models in rats. *Stroke*
13 32:2648-2657.
- 14 21. Kadota T, Shingo T, Yasuhara T, Tajiri N, Kondo A, et al. (2009) Continuous
15 intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon
16 Parkinson's disease model of rats with enhanced neurogenesis. *Brain Res* 1254:120-127.
- 17 22. Yuan WJ, Yasuhara T, Shingo T, Muraoka K, Agari T, et al. (2008)
18 Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic
19 neurons. *BMC Neurosci* 9:75.
- 20 23. Zhong J, Huang DL, Sagher O (2004) Parameters influencing augmentation of
21 cerebral blood flow by cervical stimulation. *Acta Neurochir (Wien)* 146:1227-1234.
- 22 24. Isono M, Kaga A, Fujiki M, Mori T, Hori S (1995) Effect of spinal cord
23 stimulation on cerebral blood flow in cats. *Stereotact Funct Neurosurg* 64: 40-46
- 24 25. Shealy CN, Mortimer JT, Reswick JB (1967) Electrical inhibition of pain by

- 1 stimulation of the dorsal columns: preliminary clinical report. *Anesth Analg*
2 46:489-491.
- 3 26. Kumar K, Taylor RS, Jacques L, Eidabe S, Meqlio M, et al. (2007) Spinal cord
4 stimulation versus conventional medical management for neuropathic pain: a
5 multicenter randomized controlled trial in patients with failed back syndrome. *Pain* 132:
6 179-188.
- 7 27. Kemler MA, Barendse GA, van Kleef M, de Vet HC, Rijks CP, et al. (2000)
8 Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. *N Engl J*
9 *Med* 343:618-624.
- 10 28. Melzack R, Wall PD (1965) Pain mechanisms: a new theory. *Science*
11 150:971-979.
- 12 29. Cui JG, Linderoth B, Meyerson BA (1996) Effects of spinal cord stimulation
13 on touch-evoked allodynia involve GABAergic mechanisms. An experimental study in
14 the mononeuropathic rat. *Pain* 66:287-295.
- 15 30. Cui JG, O'Connor WT, Ungerstedt U, Linderoth B, Meyerson BA (1997)
16 Spinal cord stimulation attenuates augmented dorsal horn release of excitatory amino
17 acids in mononeuropathy via a GABAergic mechanism. *Pain* 73:87-95.
- 18 31. Levin BE, Hubschmann OR (1980) Dorsal column stimulation: Effect on
19 human cerebrospinal fluid and plasma catecholamines. *Neurology* 30:65-71.
- 20 32. Linderoth B, Gazelius B, Franck J, Brodin E (1992) Dorsal column stimulation
21 induces release of serotonin and substance P in the cat dorsal horn. *Neurosurgery*
22 31:289-296; discussion 296-287.
- 23 33. Schechtmann G, Song Z, Ultenius C, Meyerson BA, Linderoth B (2008)
24 Cholinergic mechanisms involved in the pain relieving effect of spinal cord stimulation

- 1 in a model of neuropathy. *Pain* 139:136-145.
- 2 34. Song Z, Meyerson BA, Linderoth B (2008) Muscarinic receptor activation
3 potentiates the effect of spinal cord stimulation on pain-related behavior in rats with
4 mononeuropathy. *Neurosci Lett* 436:7-12.
- 5 35. Stiller CO, Cui JG, O'Connor WT, Brodin E, Meyerson BA, et al. (1996)
6 Release of gamma-aminobutyric acid in the dorsal horn and suppression of tactile
7 allodynia by spinal cord stimulation in mononeuropathic rats. *Neurosurgery*
8 39:367-374; discussion 374-365.
- 9 36. Yakhnitsa V, Linderoth B, Meyerson BA (1999) Spinal cord stimulation
10 attenuates dorsal horn neuronal hyperexcitability in a rat model of mononeuropathy.
11 *Pain* 79:223-233.
- 12 37. Hosobuchi Y (1985) Electrical stimulation of the cervical spinal cord increases
13 cerebral blood flow in humans. *Appl Neurophysiol* 48:372-376.
- 14 38. Hosobuchi Y (1991) Treatment of cerebral ischemia with electrical stimulation
15 of the cervical spinal cord. *Pacing Clin Electrophysiol* 14:122-126.
- 16 39. Meglio M, Cioni B, Visocchi M (1991) Cerebral hemodynamics during spinal
17 cord stimulation. *Pacing Clin Electrophysiol* 14:127-130.
- 18 40. Chandler MJ, Brennan TJ, Garrison DW, Kim KS, Schwartz PJ, et al. (1993) A
19 mechanism of cardiac pain suppression by spinal cord stimulation: implications for
20 patients with angina pectoris. *Eur Heart J* 14:96-105.
- 21 41. Maher J, Johnson AC, Newman R, Mendez S, Hoffmann TJ, et al. (2009)
22 Effect of spinal cord stimulation in a rodent model of post-operative ileus.
23 *Neurogastroenterol Motil* 21:672-677, e633-674.
- 24 42. Linderoth B, Gherardini G, Ren B, Lundeberg T (1995) Preemptive spinal cord

- 1 stimulation reduces ischemia in an animal model of vasospasm. *Neurosurgery*
2 37:266-271; discussion 271-262.
- 3 43. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, et al. (2005)
4 Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the
5 prevention of cerebral vasospasm following severe aneurysmal subarachnoid
6 hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter
7 phase IIa study. *J Neurosurg* 103:9-17.
- 8 44. Sagher O, Huang DL (2006) Mechanisms of spinal cord stimulation in
9 ischemia. *Neurosurg Focus* 21:E2.
- 10 45. Edvinsson L, Hara H, Uddman R (1989) Retrograde tracing of nerve fibers to
11 the rat middle cerebral artery with true blue: colocalization with different peptides. *J*
12 *Cereb Blood Flow Metab* 9:212-218.
- 13 46. Göksel HM, Karadag Ö, Turaçlar U, Taş F, Öztoprak I (2001) Nitric oxide
14 synthase inhibition attenuates vasoactive response to spinal cord stimulation in an
15 experimental cerebral vasospasm model. *Acta Neurochir (Wien)* 143:383-390;
16 discussion 390-381.
- 17 47. Visocchi M, Giordano A, Calcagni M, Cioni B, Di Rocco F, et al. (2001) Spinal
18 cord stimulation and cerebral blood flow in stroke: personal experience. *Stereotact*
19 *Funct Neurosurg* 76:262-268.
- 20 48. Drake CJ, Little CD (1995) Exogenous vascular endothelial growth factor
21 induces malformed and hyperfused vessels during embryonic neovascularization. *Proc*
22 *Natl Acad Sci USA* 92:7657-7661.
- 23 49. Silverman WF, Krum JM, Mani N, Rosenstein JM (1999) Vascular, glial and
24 neuronal effects of vascular endothelial growth factor in mesencephalic explant cultures.

- 1 Neuroscience 90:1529-1541.
- 2 50. Yasuhara T, Shingo T, Date I (2004) The potential role of vascular endothelial
3 growth factor in the central nervous system. *Rev Neurosci* 15:293-307.
- 4 51. Yasuhara T, Shingo T, Kobayashi K, Takeuchi A, Yano A, et al. (2004)
5 Neuroprotective effects of vascular endothelial growthfactor (VEGF) upon
6 dopaminergic neurons in a rat model of Parkinson's disease.
- 7 52. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, et al. (2002) Vascular endothelial growth
8 factor (VEGF) stimulates neurogenesis in vitro and in vivo. *Proc Natl Acad Sci USA*
9 99:11946-11950.
- 10 53. Jin KL, Mao XO, Greenberg DA (2000) Vascular endothelial growth factor:
11 direct neuroprotective effect in in vitro ischemia. *Proc Natl Acad Sci USA*
12 97:10242-10247.
- 13 54. Pitzer MR, Sortwell CE, Daley BF, McGuire SO, Marchionini D, et al. (2003)
14 Angiogenic and neurotrophic effects of vascular endothelial growth factor (VEGF165):
15 studies of grafted and cultured embryonic ventral mesencephalic cells. *Experimental*
16 *Neurology* 182:435-445.
- 17 55. Thevathasan W, Mazzone P, Jha A, Djamshidian A, Dileone M, et al. (2010)
18 Spinal cord stimulation failed to relieve akinesia or restore locomotion in Parkinson
19 disease. *Neurology* 74:1325-1327.

20

21

22

23

24

1 **Figure Legends**

2 **Figure Legend 1. Time course and SCS electrode, and the brain region punched**
3 **out for protein assay.** (A) Scheme showing overall experimental design. (B) Scheme
4 showing experimental design for protein assay. (C) Photograph showing SCS electrode
5 used in this study (diameter: 2mm; wire length: 60mm). (D) Scheme showing a rat
6 during stimulation. (E) Brain tissue (diameter: 3mm showing gray circle),
7 corresponding to the striatum, was punched out from both the lesioned and the intact
8 side.

9 **Figure Legend 2. The results of cylinder test and amphetamine-induced rotation**
10 **test.**

11 (A) Rats receiving 2Hz and 50Hz SCS showed reduction of the contralateral bias at 2
12 weeks after 6-OHDA lesion, compared to that of rats in control group. (B) The number
13 of amphetamine-induced rotations in all SCS groups decreased, compared to that of
14 control group. There was a significant amelioration in 50Hz SCS group, compared to
15 control group (* $p < 0.05$, $n = 10$, respectively).

16 **Figure Legend 3. Tyrosine hydroxylase (TH) immunostaining in the striatum and**
17 **the ratio to the intact side.**

18 (A) TH immunostaining in the striatum. Severe loss of TH-positive fibers was seen in
19 the lesioned striatum of control group. Preservation of TH-positive fibers was seen in
20 the lesioned striatum of all SCS groups. Scale bar: 200 μ m. (B) The all SCS groups
21 showed significant preservation of TH-positive fibers in the lesioned striatum,
22 compared to those in control group (* $p < 0.05$, $n = 10$, respectively).

23 **Figure Legend 4. TH immunostaining in the substantia nigra pars compacta (SNc),**
24 **and the ratio to the intact side.**

1 (A) TH immunostaining in the intact SNc. Severe loss of TH-positive neurons was seen
2 in the lesioned side SNc of control group. Preservation of TH-positive neurons was seen
3 at the lesioned side SNc of 50Hz SCS group. Scale bar: 200 μ m. (B) Significant
4 preservation of TH-positive neurons in the lesioned-side SNc of 50Hz SCS group,
5 compared to those of control group (* p <0.05, n =10, respectively).

6 **Figure Legend 5. Results of ELISA analysis for VEGF and GDNF.**

7 (A, B) In the lesioned striatum, VEGF was significantly increased by SCS at 1 week
8 after 6-OHDA lesion (* p <0.05). At 2 weeks after 6-OHDA lesion, VEGF level in the
9 lesioned striatum also appeared elevated, but did not reach statistical significance.

10 (C, D) GDNF in the striatum of both sides was not significantly increased by SCS at 1
11 and 2 weeks after 6-OHDA lesion. (C-lesion: control group lesioned side Striatum;
12 C-intact: control group intact side Striatum; S-lesion: 50Hz SCS group lesioned side
13 Striatum; S-intact: 50Hz SCS group intact side Striatum, n =10, respectively)